MX2017012991A - Combinaciones de amisulprida y otro antiemetico para tratar nausea y vomito. - Google Patents
Combinaciones de amisulprida y otro antiemetico para tratar nausea y vomito.Info
- Publication number
- MX2017012991A MX2017012991A MX2017012991A MX2017012991A MX2017012991A MX 2017012991 A MX2017012991 A MX 2017012991A MX 2017012991 A MX2017012991 A MX 2017012991A MX 2017012991 A MX2017012991 A MX 2017012991A MX 2017012991 A MX2017012991 A MX 2017012991A
- Authority
- MX
- Mexico
- Prior art keywords
- amisulpride
- chemotherapy
- day
- vomiting
- antiemetic
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/473—Quinolines; Isoquinolines ortho- or peri-condensed with carbocyclic ring systems, e.g. acridines, phenanthridines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
- A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Hospice & Palliative Care (AREA)
- Otolaryngology (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Un kit comprende por lo menos una dosis unitaria no inyectable IV de amisulprida y por lo menos una dosis de un antiemético de fase aguda, para el uso simultáneo, separado o secuencial en el tratamiento o prevención de náusea y/o vómito inducido por quimioterapia o radioterapia en un sujeto, en donde el sujeto está recibiendo o ha recibido un régimen de tratamiento de quimioterapia o radioterapia, y en donde el régimen de dosificación comprende la administración del o cada antiemético de fase aguda en el día 1, el día 1 que es el mismo día en que se administra una quimioterapia o radioterapia, y la administración de las, o por lo menos una de las, dosis unitarias no inyectables IV de amisulprida en el día 2. También se proporciona un kit que comprende por lo menos una dosis unitaria no inyectable IV de amisulprida y por lo menos una dosis unitaria de amisulprida IV. Además se proporciona una formulación no inyectable IV de amisulprida, para el uso en el tratamiento o prevención de náusea y/o vómito inducido por quimioterapia o radioterapia de fase retardada en un sujeto.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB1506116.1A GB201506116D0 (en) | 2015-04-10 | 2015-04-10 | Kit and combination therapy for nausea and vomiting |
| PCT/GB2016/050998 WO2016162695A1 (en) | 2015-04-10 | 2016-04-11 | Combinations of amisulpride and another anti-emetic for treating nausea and vomiting |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MX2017012991A true MX2017012991A (es) | 2018-02-01 |
| MX388735B MX388735B (es) | 2025-03-20 |
Family
ID=53333601
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2017012991A MX388735B (es) | 2015-04-10 | 2016-04-11 | Combinaciones de amisulprida y otro antiemetico para tratar nausea y vomito. |
Country Status (22)
| Country | Link |
|---|---|
| US (1) | US10322106B2 (es) |
| EP (1) | EP3280392B1 (es) |
| JP (1) | JP6812360B2 (es) |
| KR (2) | KR20240125705A (es) |
| CN (1) | CN107872975A (es) |
| AU (1) | AU2016246104B2 (es) |
| CA (1) | CA2982251C (es) |
| CY (1) | CY1124184T1 (es) |
| DK (1) | DK3280392T3 (es) |
| ES (1) | ES2866933T3 (es) |
| GB (1) | GB201506116D0 (es) |
| HR (1) | HRP20210624T1 (es) |
| HU (1) | HUE054165T2 (es) |
| IL (2) | IL295650A (es) |
| LT (1) | LT3280392T (es) |
| MX (1) | MX388735B (es) |
| PL (1) | PL3280392T3 (es) |
| PT (1) | PT3280392T (es) |
| RS (1) | RS61760B1 (es) |
| SI (1) | SI3280392T1 (es) |
| SM (1) | SMT202100216T1 (es) |
| WO (1) | WO2016162695A1 (es) |
Families Citing this family (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB201618425D0 (en) * | 2016-11-01 | 2016-12-14 | Acacia Pharma Ltd | method |
| GB201702250D0 (en) * | 2017-02-10 | 2017-03-29 | Acacia Pharma Ltd | Method |
| WO2019113084A1 (en) | 2017-12-05 | 2019-06-13 | Sunovion Pharmaceuticals Inc. | Crystal forms and production methods thereof |
| CN112118838A (zh) | 2017-12-05 | 2020-12-22 | 赛诺维信制药公司 | 非外消旋混合物及其用途 |
| PH12021553056A1 (en) * | 2019-06-04 | 2023-09-11 | Sunovion Pharmaceuticals Inc | Modified release formulations and uses thereof |
| US20250206757A1 (en) | 2022-03-21 | 2025-06-26 | Gasherbrum Bio, Inc. | 5,8-dihydro-1,7-naphthyridine derivatives as glp-1 agonists for the treatment of diabetes |
| US20250250269A1 (en) | 2022-04-14 | 2025-08-07 | Gasherbrum Bio, Inc. | Heterocyclic glp-1 agonists |
| WO2024125602A1 (en) | 2022-12-15 | 2024-06-20 | Gasherbrum Bio, Inc. | Salts and solid forms of a compound having glp-1 agonist activity |
| CN120712261A (zh) | 2022-12-22 | 2025-09-26 | 加舒布鲁姆生物公司 | 杂环的glp-1激动剂 |
| JP2026501286A (ja) | 2022-12-22 | 2026-01-14 | ガシャーブラム・バイオ・インコーポレイテッド | ヘテロ環式ｇｌｐ－１アゴニスト |
| WO2024169952A1 (en) | 2023-02-16 | 2024-08-22 | Gasherbrum Bio, Inc. | Heterocyclic glp-1 agonists |
| US20250019389A1 (en) | 2023-06-30 | 2025-01-16 | Gasherbrum Bio, Inc. | Heterocyclic agonists |
| AR133240A1 (es) | 2023-07-13 | 2025-09-10 | Aconcagua Bio Inc | Compuestos, composiciones y métodos |
| WO2025015269A1 (en) | 2023-07-13 | 2025-01-16 | Aconcagua Bio, Inc. | Compounds, compositions, and methods |
| WO2025045208A1 (en) | 2023-08-31 | 2025-03-06 | Gasherbrum Bio, Inc. | Heteroaryl-heterocycloalkyl-based glp-1 agonists |
| WO2025137307A1 (en) | 2023-12-20 | 2025-06-26 | Gasherbrum Bio, Inc. | Heterocyclic glp-1 agonists |
| WO2025171341A2 (en) | 2024-02-08 | 2025-08-14 | Aconcagua Bio, Inc. | Compounds and compositions for treating conditions associated with calcitonin receptor and/or amylin receptor activity |
| WO2025171340A1 (en) | 2024-02-08 | 2025-08-14 | Aconcagua Bio, Inc. | The treatment of calcitonin- and/or amylin-receptor associated conditions |
| WO2025189141A1 (en) | 2024-03-08 | 2025-09-12 | Annapurna Bio, Inc. | Methods for treating obesity and increasing weight loss |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB201003962D0 (en) | 2010-03-10 | 2010-04-21 | Tangentix Ltd | Multimedia content delivery system |
| GB201004020D0 (en) * | 2010-03-11 | 2010-04-21 | Acacia Pharma Ltd | New therapeutic use |
| WO2013040164A1 (en) * | 2011-09-13 | 2013-03-21 | Biomed Valley Discoveries, Inc. | Compositions and methods for treating metabolic disorders |
-
2015
- 2015-04-10 GB GBGB1506116.1A patent/GB201506116D0/en not_active Ceased
-
2016
- 2016-04-11 LT LTEP16716659.4T patent/LT3280392T/lt unknown
- 2016-04-11 KR KR1020247026775A patent/KR20240125705A/ko active Pending
- 2016-04-11 ES ES16716659T patent/ES2866933T3/es active Active
- 2016-04-11 HU HUE16716659A patent/HUE054165T2/hu unknown
- 2016-04-11 JP JP2017553076A patent/JP6812360B2/ja active Active
- 2016-04-11 EP EP16716659.4A patent/EP3280392B1/en active Active
- 2016-04-11 CA CA2982251A patent/CA2982251C/en active Active
- 2016-04-11 HR HRP20210624TT patent/HRP20210624T1/hr unknown
- 2016-04-11 MX MX2017012991A patent/MX388735B/es unknown
- 2016-04-11 PL PL16716659T patent/PL3280392T3/pl unknown
- 2016-04-11 DK DK16716659.4T patent/DK3280392T3/da active
- 2016-04-11 CN CN201680030994.9A patent/CN107872975A/zh active Pending
- 2016-04-11 US US15/565,479 patent/US10322106B2/en active Active
- 2016-04-11 SM SM20210216T patent/SMT202100216T1/it unknown
- 2016-04-11 AU AU2016246104A patent/AU2016246104B2/en active Active
- 2016-04-11 PT PT167166594T patent/PT3280392T/pt unknown
- 2016-04-11 IL IL295650A patent/IL295650A/en unknown
- 2016-04-11 KR KR1020177032393A patent/KR102711661B1/ko active Active
- 2016-04-11 WO PCT/GB2016/050998 patent/WO2016162695A1/en not_active Ceased
- 2016-04-11 SI SI201631183T patent/SI3280392T1/sl unknown
- 2016-04-11 RS RS20210407A patent/RS61760B1/sr unknown
-
2017
- 2017-10-08 IL IL254929A patent/IL254929A0/en unknown
-
2021
- 2021-05-20 CY CY20211100442T patent/CY1124184T1/el unknown
Also Published As
| Publication number | Publication date |
|---|---|
| IL254929A0 (en) | 2017-12-31 |
| HUE054165T2 (hu) | 2021-08-30 |
| HK1250913A1 (en) | 2019-01-18 |
| PT3280392T (pt) | 2021-03-12 |
| RS61760B1 (sr) | 2021-05-31 |
| AU2016246104A1 (en) | 2017-11-30 |
| PL3280392T3 (pl) | 2021-10-18 |
| CA2982251C (en) | 2023-06-13 |
| LT3280392T (lt) | 2021-04-26 |
| JP2018510898A (ja) | 2018-04-19 |
| JP6812360B2 (ja) | 2021-01-13 |
| CY1124184T1 (el) | 2022-07-22 |
| KR102711661B1 (ko) | 2024-10-02 |
| SI3280392T1 (sl) | 2021-08-31 |
| ES2866933T3 (es) | 2021-10-20 |
| IL295650A (en) | 2022-10-01 |
| HRP20210624T1 (hr) | 2021-05-28 |
| KR20240125705A (ko) | 2024-08-19 |
| KR20180016350A (ko) | 2018-02-14 |
| US20180071249A1 (en) | 2018-03-15 |
| EP3280392B1 (en) | 2021-02-24 |
| EP3280392A1 (en) | 2018-02-14 |
| AU2016246104B2 (en) | 2018-12-13 |
| US10322106B2 (en) | 2019-06-18 |
| MX388735B (es) | 2025-03-20 |
| CN107872975A (zh) | 2018-04-03 |
| SMT202100216T1 (it) | 2021-05-07 |
| GB201506116D0 (en) | 2015-05-27 |
| DK3280392T3 (da) | 2021-03-08 |
| CA2982251A1 (en) | 2016-10-13 |
| WO2016162695A1 (en) | 2016-10-13 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2017012991A (es) | Combinaciones de amisulprida y otro antiemetico para tratar nausea y vomito. | |
| CO2019001537A2 (es) | Sistema y método para terapia médica controlada | |
| MX2019008028A (es) | Regimenes de dosificacion de inmunoconjugado anti-receptor en folato 1 (folr1). | |
| MX2017005106A (es) | Metodos y composiciones para dosificacion en terapia celular adoptiva. | |
| CO2017001994A2 (es) | Compuestos activos hacia bromodominios | |
| AR105027A1 (es) | Métodos de tratamiento del cáncer de mama localmente avanzado o metastásico usando antagonistas del eje de pd-1 y taxanos | |
| MX2017006312A (es) | Metodos para el tratamiento tumoral utilizando el anticuerpo biespecifico cd3xcd20. | |
| MX2018001723A (es) | Conjugados farmaco-multiligando y usos de los mismos. | |
| BR112016013861A2 (pt) | conjugados de droga e anticorpo, compostos, método de tratamento e composição farmacêutica | |
| MX379297B (es) | Compuestos alqueno tetrasustituidos y su uso. | |
| MX2018003028A (es) | Reduccion de los niveles o de la actividad de los linfocitos t reguladores sistemicos para el tratamiento de enfermedades y lesiones del sistema nervioso central (snc). | |
| MX2017000627A (es) | Metodos para tratar pacientes con hipercolesterolemia familiar heterocigota (hfhe). | |
| AR108021A1 (es) | Conjugados de anticuerpo-principio activo (adcs) de inhibidores de ksp con anticuerpos anti-b7h3 | |
| MX2021009222A (es) | Regimenes de dosificacion de inmunoconjugado anti-receptor 1 de folato (folr1). | |
| AR096892A1 (es) | Una combinación farmacéutica para el tratamiento del melanoma | |
| MX2018005715A (es) | Uso de antagonistas del receptor ep4 para el tratamiento de cancer de higado asociado con nash. | |
| MX2018015022A (es) | Métodos para el tratamiento de la enfermedad de alzheimer. | |
| AR097619A1 (es) | Uso de inhibidores de acetil-coa carboxilasa para tratar acné vulgaris | |
| CL2021001636A1 (es) | Composición farmacéutica para el tratamiento de la hipertensión arterial pulmonar | |
| MX2017008486A (es) | Combinaciones del inhibidor de tirosina cinasa de bruton (btk) y regimenes de dosificacion. | |
| MX2019001850A (es) | Formulaciones para administracion oral de principios activos. | |
| MX2018013873A (es) | Irinotecan nanoliposomico para usarse en el tratamiento del cancer de pulmon de celulas pequeñas. | |
| CL2019003533A1 (es) | Uso de vibegron para tratar vejiga sobreactiva. | |
| BR112018002530A2 (pt) | combinações e usos e tratamentos destas | |
| MX2017013636A (es) | Combinacion de dosis fija resistente a la manipulacion que proporciona una liberacion rapida de dos farmacos desde diferentes particulas. |